Q.01

How does the FDA pathway for modified existing drugs work?

A modified version of an already-approved drug usually goes to the FDA as a 505(b)(2) application. This is a full new drug application (NDA), but it can rely on safety and effectiveness investigations that the applicant did not conduct and has no right of reference to. You then supply only the data needed to support your change. If the change needs nothing beyond bioavailability or bioequivalence data, the route is instead a generic (ANDA) application, sometimes after a suitability petition.

Approach: I read FD&C Act section 505 (21 U.S.C. 355, 2023 U.S. Code edition) and the current eCFR text of 21 CFR Part 314. FDA's CDER guidance documents on 505(b)(2) are not in the datasets I can search, so this is the statute and regulations only.

1. What a 505(b)(2) application is

  • Definition: an NDA for which "at least some of the investigations… relied upon by the applicant for approval… were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use" [1]. The statute uses the same wording [2].
  • Scope: it covers "a drug product that represents a modification of a listed drug (e.g., a new indication or new dosage form) and for which investigations, other than bioavailability or bioequivalence studies, are essential to the approval." The application "need contain only that information needed to support the modification(s)" (21 CFR 314.54(a)) [3].
  • Excluded: it may not be used where the product's only difference is that its active ingredient is absorbed less, or unintentionally absorbed more slowly, than the listed drug (314.54(b)) [3].

2. How it differs from a generic (ANDA) route

  • ANDA limits: the Act "does not permit approval of an ANDA for a new indication," or of other changes where non-BA/BE investigations are essential (314.54(a)) [3].
  • Suitability petition (314.93): for a change in route, dosage form or strength, or swapping one active ingredient in a combination, you can petition to file an ANDA. FDA "will approve or disapprove" within 90 days. It will deny the petition if, among other grounds, "investigations must be conducted to show the safety and effectiveness," meaning animal or clinical data are needed. It will also deny it if an NDA has already been approved for that change [4]. In practice, a petition FDA rejects for that reason sends the product to the 505(b)(2) route.

3. What the application must contain (21 CFR 314.54(a)(1))

  • Required 314.50 sections: 314.50(a), (b), (c), (d)(1), (d)(3), (e) and (g). The nonclinical, clinical, statistical and related sections are needed "as needed to support the safety and effectiveness" of the change [3].
  • Listed drug(s) relied on: you must identify each one. This must include an NDA product that is pharmaceutically equivalent to yours and was approved before you submit. The rule says such an applicant "implicitly relies upon" one pharmaceutically equivalent listed drug [3].
  • Other contents: a certification if you seek only a new indication, your own patent information, patent certifications, and any exclusivity claim under 314.50(j) [3].

4. Patent certification and notice

  • Certifications: for each listed patent claiming the drug relied on, or a use of it, you certify one of four things (314.50(i); 21 U.S.C. 355(b)(2)) [5][2]:
    • Paragraph I: the patent information has not been submitted.
    • Paragraph II: the patent has expired.
    • Paragraph III: the date the patent will expire.
    • Paragraph IV: the patent is invalid, unenforceable or not infringed.
  • Method-of-use patents: if your proposed labeling does not cover the patented use, you may file a statement saying so instead [5].
  • Paragraph IV notice (314.52): you must send notice to the patent owner and the NDA holder. It goes out on or after filing and no later than 20 days after the postmark on FDA's paragraph IV acknowledgment letter. It must include a detailed factual and legal basis for your position. The 45-day period for the patent owner to sue starts the day after they receive it [6].

5. When FDA can approve it (21 CFR 314.107)

  • Latest blocking date governs: approval comes on the last of the dates on which each relevant patent stops blocking it [7].
  • 30-month stay: if suit is brought within 45 days of receiving a paragraph IV notice, approval "may be approved 30 months after" receipt of notice. Where the listed drug has new chemical entity (NCE) exclusivity and suit is filed in year 5, the date is 7½ years from that drug's approval instead. Court decisions, patent-owner consent or dismissal can end the stay earlier [7].
  • Tentative approval: if your application is ready but blocked by patents or exclusivity, FDA issues a tentative approval. That "is not an approved drug" until a final approval letter issues [1].
  • Exclusivity delays: FDA also delays approval for the listed drug's 314.108 exclusivity, orphan exclusivity under section 527, pediatric exclusivity under 505A, and section 505E exclusivity (314.107(d)) [7].

6. Exclusivity: what blocks you and what you can earn (21 CFR 314.108)

  • Blocking you (NCE): no 505(b)(2) application may be submitted for 5 years after an NCE's approval. The exception is year 4, if you include a paragraph IV certification [8].
  • Blocking you (3-year): an earlier NDA or supplement backed by "new clinical investigations… essential to approval," conducted or sponsored by its holder, bars FDA from approving your 505(b)(2) application for those conditions for 3 years [8].
  • Earning it: your own 505(b)(2) product can get that same 3-year exclusivity if your new clinical studies meet those criteria. Claiming it requires these items (314.50(j)) [5]:
    • a certification that each study is a "new clinical investigation";
    • a literature search showing published data could not support approval;
    • proof that you conducted or sponsored the studies, through the IND, or by funding 50% or more or explaining why FDA should treat you as the sponsor.

7. Limits after submission

  • Same drug only: you "may not amend or supplement" a 505(b)(2) application to seek approval of a different drug. Adding a different strength is allowed (21 U.S.C. 355(b)(4)) [2].
Q.02

How does it differ from a generic drug application?

The core difference is what each application has to prove. An ANDA (generic) shows that your product is the same as a reference listed drug and bioequivalent to it, and relies entirely on FDA's earlier finding of safety and effectiveness. A 505(b)(2) application is a full NDA: it relies on studies you didn't run, but you add your own nonclinical or clinical data for whatever you have changed. That is why only 505(b)(2) can be used for something like a new indication.

Approach: I compared the current eCFR text of 21 CFR Part 314 (314.54 for 505(b)(2); 314.92, 314.94, 314.95, 314.107, 314.108 and 314.127 for ANDAs). FDA's CDER guidance documents on either pathway are not in the datasets I can search.

1. Which products qualify

ANDA (505(j))505(b)(2)
Basic ruleThe product must be the "same as" a listed drug: "identical in active ingredient(s), dosage form, strength, route of administration, and conditions of use." Conditions protected by patent or exclusivity can be left out [9]A modification of a listed drug, such as a new indication or dosage form, where studies "other than bioavailability or bioequivalence studies, are essential to the approval" [3]
Allowed differencesOnly a different route, dosage form or strength, or one different active ingredient in a combination product, and only through an approved suitability petition (314.93) [9][10]Any change your own data can support, except a product whose only difference is less absorption or unintentionally slower absorption [3]
Conditions of useThe ANDA must include a statement that the proposed conditions of use "have been previously approved for the reference listed drug" [11]A new indication is a stated example of what the route is for [3]

2. What the dossier contains

  • ANDA (314.94(a)): the ANDA "must refer to a listed drug," normally the reference standard FDA picked for bioequivalence testing. It then shows sameness: an active-ingredient sameness statement, and statements that route, dosage form and strength are the same. It needs a complete study report for the bioequivalence study you rely on, plus the 314.50(d)(1) CMC information. It also needs samples, patent certifications and a financial certification or disclosure [11]. No nonclinical or clinical efficacy sections are listed.
  • 505(b)(2) (314.54(a)(1)): the 314.50 NDA sections, including nonclinical, clinical and statistical sections "as needed to support the safety and effectiveness" of the change. You also identify every listed drug you rely on [3].

3. Labeling and inactive ingredients

  • Labeling: ANDA labeling "must be the same as the labeling approved for the reference listed drug." The permitted differences are:
    • changes allowed by an approved petition;
    • differences because the product comes from a different manufacturer, such as expiration date, formulation, bioavailability or pharmacokinetics;
    • carve-outs of indications protected by patent or exclusivity [11].
  • Inactive ingredients: the ANDA rules are strict.
    • Parenteral, ophthalmic, otic and topical products generally must contain the same inactive ingredients as the reference drug (for parenteral, ophthalmic and otic products, also in the same concentration). Only listed categories may differ, such as preservative, buffer or antioxidant for parenteral products [11].
    • FDA "will refuse to approve" an ANDA whose inactive ingredients or composition raise serious safety or efficacy questions. Examples include an excipient never before approved for that route, or "a delivery or a modified release mechanism never before approved for the drug" [10].
    • A product like that would need to go the 505(b)(2) route instead.

4. Patent certification and notice

  • Same four certifications: both routes use paragraphs I to IV and the method-of-use statement (314.94(a)(12) for ANDAs, 314.50(i) for 505(b)(2)) [11].
  • Notice timing differs:
    • An ANDA applicant sends paragraph IV notice on or after receiving FDA's paragraph IV acknowledgment letter, and no later than 20 days after its postmark. Notice sent earlier "is invalid" [12].
    • A 505(b)(2) applicant sends notice on or after the filing date under 314.101(a)(2) or (3), within the same 20-day limit [6].

5. Exclusivity

  • Blocks that apply to both routes:
    • NCE exclusivity: no 505(b)(2) application "or ANDA" may be submitted for 5 years, or 4 years with a paragraph IV certification [8].
    • 3-year new-clinical-investigation exclusivity: this bars FDA from approving either type of application for the protected conditions [8].
  • 180-day exclusivity (ANDA only): a subsequent ANDA applicant with a paragraph IV certification "will not be approved" while a first applicant is eligible for, or holds, 180-day exclusivity. That period cannot run past the expiry of the patent it is based on [7].
    • Exception: FDA "may immediately approve" later ANDAs if the first applicant is not actively pursuing approval [7].
  • 3-year exclusivity (505(b)(2) only): your own 505(b)(2) product can earn it if its new clinical investigations meet the 314.108 criteria (covered in my previous answer). ANDAs have no such route because they rely only on bioequivalence data.

6. Grounds for refusal

FDA "will refuse to approve" an ANDA on grounds that come straight from sameness (314.127(a)) [10]:

  • the data don't show the conditions of use were previously approved;
  • the data don't show the active ingredient, route, dosage form or strength is the same;
  • the data don't show bioequivalence;
  • the labeling is not the same as the reference drug's;
  • the reference drug has been withdrawn or suspended for safety or effectiveness reasons;
  • for a petition-based ANDA, an NDA "subsequently has been approved for the change described in the approved petition."

So the practical test is this: if sameness plus bioequivalence (or an approved suitability petition) covers your product, the ANDA route is available. If you need any safety or efficacy data beyond bioavailability or bioequivalence, the product goes the 505(b)(2) route.

Q.03